Evidence map›Paper›PMID 36267813›Full record

ReviewOxidative medicine and cellular longevity2022

Role of AMPK in Myocardial Ischemia-Reperfusion Injury-Induced Cell Death in the Presence and Absence of Diabetes.

Nirupama Kandula, Saurabh Kumar, Venkata Kiran Kumar Mandlem, Aneela Siddabathuni, Sanjay Singh, Ramoji Kosuru

Open access · hybridAbstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Nirupama KandulaDepartment of Microbiology, GSL Medical College, Rajahmahendravaram, Andhra Pradesh 533296, India.ORCID https://orcid.org/0000-0002-2287-8127
Saurabh KumarBioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, India.ORCID https://orcid.org/0000-0002-2143-6415
Venkata Kiran Kumar MandlemDepartment of Pharmacology, CMR College of Pharmacy, Medchal, Hyderabad, Telangana 501401, India.ORCID https://orcid.org/0000-0003-2015-478X
Aneela SiddabathuniDepartment of Pharmacology, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Andhra Pradesh 522601, India.ORCID https://orcid.org/0000-0003-0832-3851
Sanjay SinghBabasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow, Uttar Pradesh 226025, India.ORCID https://orcid.org/0000-0002-6748-0585
Ramoji KosuruVersiti Blood Research Institute, Milwaukee, Wisconsin, USA 53226.ORCID https://orcid.org/0000-0002-7394-7217
Babasaheb Bhimrao Ambedkar University · INCentral Institute of Medicinal and Aromatic Plants · INCMR University · INGSL Medical College & General Hospital · INVersiti Blood Center of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP-activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down-regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non-diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes-associated cardiovascular complications, such as myocardial ischemia-reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes-associated myocardial ischemia-reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia-reperfusion injury in the presence and absence of diabetes.

Indexed as

Diabetes Mellitus, Type 2Myocardial Reperfusion InjuryAMP-Activated Protein KinasesAnimalsApoptosisAutophagyHumansAMP-Activated Protein Kinases

Identifiers

PMID36267813
PMCPMC9578802
OpenAlexW4304471515

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.